Post A Reply
my profile
login
|
register
|
search
|
faq
|
forum home
»
Allstocks.com's Bulletin Board
»
.11 and Up!
»
NRGX Gene therapy
» Post A Reply
Post A Reply
Login Name:
Password:
Message Icon:
Message:
HTML is enabled.
UBB Code™ is enabled.
[QUOTE]Originally posted by BooDog: [QB] What a retrace eh? Watching for this to drop a bit more since it still isn't getting the volume attention. Low volumes and a few warrants and convertibles. http://www.neurologix.net NEUROLOGIX INC at C.E. Unterberg, Towbin Emerging Growth Conference Tuesday, July 10, 2007 4:30 p.m. ET [URL=http://www.wsw.com/webcast/ceut6/register.aspx?conf=ceut6&page=nrgx&url=http%3A//www.wsw.com/webcast/ceut6/nrgx/]http://www.wsw.com/webcast/ceut6/register.aspx?conf=ceut6&page=nrgx&url=http%3A/ /www.wsw.com/webcast/ceut6/nrgx/[/URL] Fact sheet: http://media.corporate-ir.net/media_files/irol/10/106413/NRGXFactSheet1.pdf BTW – there are only a couple boards talking about this (and I’m keeping my posts for this one here) so if things start heating up remember where you heard it! LOL. a little info... Overview Neurologix, Inc., a leader in the development of innovative therapies for the brain and central nervous system, utilizes gene therapy and other novel technologies. The central nervous system ("CNS") is a new and particularly exciting target for gene therapy because its unique properties prevent the successful treatment of many neurological disorders by conventional means such as drug therapy and surgery. The Company has developed numerous technologies designed to deliver gene therapy as a treatment for CNS disorders.Gene therapy works by intervening and altering the instruction set of a cell in order to either compensate for a missing or ineffective gene or provide an entirely new property to specific cells. The Company's first-generation proprietary gene transfer technology platform ('NLX') was approved by the FDA for Phase I clinical trials for the treatment of 12 patients with Parkinson's disease. All patients have undergone surgical gene therapy at The New York Presbyterian Hospital/Weill Medical College of Cornell University and have been followed with both neurological evaluations and PET scans of the brain at North Shore University Hospital. The basis of the Company's gene transfer technology is its proprietary ability to utilize specific vectors along with cell promoters in order to (1) target specific cells (those requiring new instruction), (2) effectively transduce the cell or deliver the gene, and (3) show stable and persistent expression (i.e., therapy that works consistently for a period of time). The Company's first-generation gene transfer technology uses an adeno-associated virus ("AAV") vector as the delivery mechanism for the cells. The use of viral vectors takes advantage of the natural efficiency with which viruses deliver genes to cells. Future-generation gene transfer technology may utilize other vectors as well as a proprietary promoter (enabler) technology for the long-term and regulatable expression necessary for gene transfer and function. In addition, the Company has other novel technologies in development for the treatment of Parkinson's Disease ("PD"), epilepsy, and other CNS related disorders. At May 11, 2007 there were outstanding 26,542,924 shares of the Registrant's Common Stock, $.001 par value. 60mm authorized. Treatment Phase Details Click on Phase Number for DETAILED INFORMATION on that phase Phase Status Title of Trial Start Date Duration Weeks Sponsor Preclinical Phase Completed Unknown Neurologix, Inc. (USA) Phase 1 Phase Completed Safety Study of Subthalamic Nucleus Gene Therapy for Parkinson's Disease 8/18/2003 48 Neurologix, Inc. (USA) Phase 2 Not Started Glutamic Acid Decarboxylase (GAD) Gene Therapy, Phase 2 Fourth Quarter, 2007 52 weeks Neurologix, Inc. (USA) Phase 3 Not Started Neurologix, Inc. (USA) Phase 4 Not Started Neurologix, Inc. (USA) ------------- Obviously we have plenty of time to go through this pretty thoroughly. There are some deep pockets funding this. This is NOT A BUY recommendation, if anything a "wait". The last run was premature (and purdy!) but not enough to hold it up. I think it may fall a bit more. Do your own DD. Still about 1 year to go to get through phase II but it has some good eyes on it imo. filings [URL=http://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000356591&owner=include&count=40-----------]http://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000356591&owner=i nclude&count=40-----------[/URL] my other thread from the hotstocks section [URL=http://www.allstocks.com/stockmessageboard/ubb/ultimatebb.php/ubb/get_topic/f/2/t/014279/p/1.html#000000]http://www.allstocks.com/stockmessageboard/ubb/ultimatebb.php/ubb/get_topic/f/2/ t/014279/p/1.html#000000[/URL] Here are some things to consider that I found a very interesting read when looking into a biotech. IMO you can apply this to other sectors as well but this read is mainly for biotech… http://www.fool.com/investing/general/2004/08/02/whats-a-drug-worth.aspx http://www.biogeneticventures.com/news/feature2.pdf http://www.maricopa.edu/bwd/pdfs/biotechpb.pdf ------------------------------------------------------------ NEUROLOGIX INC (OTC BB:NRGX.OB) Last Trade: 1.14 Trade Time: 3:59PM ET Change: 0.02 (1.72%) Prev Close: 1.16 Open: 1.20 Bid: 1.13 x 500 Ask: 1.17 x 500 1y Target Est: N/A Day's Range: 1.14 - 1.20 52wk Range: 0.45 - 4.50 Volume: 37,500 Avg Vol (3m): 59,313.9 Market Cap: 30.26M P/E (ttm): N/A EPS (ttm): -0.40 Div & Yield: N/A (N/A) [URL=http://imageshack.us] [IMG]http://img73.imageshack.us/img73/5576/nrgx1gb9.png[/IMG][/URL] [/QB][/QUOTE]
Instant Graemlins
Instant UBB Code™
What is UBB Code™?
Options
Disable Graemlins in this post.
*** Click here to review this topic. ***
Contact Us
|
Allstocks.com Message Board Home
© 1997 - 2021 Allstocks.com. All rights reserved.
Powered by
Infopop Corporation
UBB.classic™ 6.7.2